In conclusion, our systematic review and meta-analysis found that osimertinib showed meaningful CNS efficacy in terms of radiologic response and a manageable safety profile in patients with LM from EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.